Citi analysts reiterated a Buy rating on Gilead Sciences, Inc. (NASDAQ:GILD) stock and maintained a $125 price target.

The latest findings support the expectation that the combination therapy will become the new SOC in PD-L1-positive TNBC.

GILD posts strong phase III results for Trodelvy plus Keytruda, cutting TNBC progression risk by 35% compared with standard ...

The drug candidate, trevogrumab, in combination with Novo Nordisk's popular obesity drug Wegovy, chemically known as semaglutide, helped patients preserve muscle and increase fat loss in patients, ...

The data may change how patients are treated following a diagnosis for advanced triple-negative breast cancer, one expert ...

Gilead has already announced intentions to bring the data, which demonstrated a 35 percent reduction in risk of progression ...

As ASCO 2025 commenced in Chicago on Friday 30th May, pharmaphorum headed over to the Windy City’s Willis Tower for Johnson & ...

Gilead Sciences' TROP2-targeting drug Trodelvy is already used as a third-line treatment for PD-L1-positive triple-negative ...

First-line treatment with sacituzumab govitecan plus pembrolizumab showed significant improvement in PFS vs. chemotherapy ...

CHICAGO -- Combining pembrolizumab (Keytruda) with sacituzumab govitecan (SG, Trodelvy) instead of chemotherapy as first-line ...

A new clinical trial has shown that combining Gilead Sciences, Inc. (NASDAQ:GILD)’s Trodelvy with Merck & Co., Inc. (NYSE:MRK ...